ATRC
NEUTRAL
$39.07
Live
AtriCure, Inc. · NASDAQ
Target $52.78
(+35.1%)
$28.29
52W Range
$43.18
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.94B
P/E
N/A
ROE
-6.1%
Profit margin
-5.6%
Debt/Equity
0.16
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
65%
ATRC has a Piotroski F-Score of 5/9, indicating stable financial health, but lacks an Altman Z-Score for distress risk assessment. The company shows strong revenue growth (15.8% YoY) and impressive earnings surprise trends, yet remains unprofitable with negative margins and ROE. High valuation multiples and insider selling offset bullish analyst sentiment and improving operational trends. The stock trades at a premium to the target, suggesting limited near-term upside despite growth potential.
Key Strengths
Strong revenue growth of 15.8% YoY, outpacing many peers in the medical instruments sector
Exceptional quarterly earnings surprise history, averaging +72.1% over the last four quarters
High gross margin of 74.87%, reflecting pricing power and low production costs
Solid balance sheet with a current ratio of 3.87 and quick ratio of 2.71, indicating strong liquidity
Low debt/equity ratio of 0.16, suggesting conservative capital structure and low leverage risk
Key Risks
Negative profitability metrics: profit margin (-5.55%), operating margin (0.15%), and ROE (-6.11%) indicate ongoing losses
Forward P/E of -298.24 reflects expectations of continued earnings losses, raising sustainability concerns
Insider selling activity: $1.33M in sales over the past 6 months with no buys, signaling lack of confidence from insiders
Lack of key financial data (Altman Z-Score, cash/debt figures, free cash flow) limits ability to assess solvency and intrinsic value
Valuation appears stretched with Price/Book of 4.08 and Price/Sales of 3.75 despite negative earnings
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
44
Moderate
35
70
60
55
0
AI Verdict
Cautiously optimistic with significant risks
Key drivers: Revenue growth and earnings surprise momentum, Strong liquidity and low leverage, Negative earnings and insider selling as counterweights, High valuation multiples
Confidence
70%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Low debt/equity ratio supports capital structure safety
Watchpoints
- Price/Book of 4.08 is high for a company with negative ROE
- Price/Sales of 3.75 elevated relative to unprofitable status
- Forward P/E deeply negative at -298.24
- No Graham Number or Intrinsic Value available for benchmarking
Future
70/100
Ref Growth rates
Positives
- Revenue growth of 15.80% YoY
- Year-over-Year EPS growth of +94.1%
- Q/Q EPS growth of +50.0%
- Analyst target price of $52.78 implies 35% upside
Watchpoints
- Forward P/E negative, indicating expected continued losses
- No free cash flow or operating cash flow data to confirm sustainability
Past
60/100
Ref Historical trends
Positives
- 3 out of last 4 quarters beat estimates
- Consistent pattern of positive earnings surprises over 25 quarters
- Progressive narrowing of losses from -$0.54 to -$0.01 per share
Watchpoints
- Company has not reported a positive EPS in the tracked history
- Mixed performance with occasional misses (e.g., -8.3% surprise in Q1 2024)
Health
55/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 5/9 indicates stable financial condition
- Current ratio of 3.87 and quick ratio of 2.71 show strong short-term liquidity
- Debt/equity ratio of 0.16 is very low
Watchpoints
- No Altman Z-Score available to assess bankruptcy risk
- ROA of -2.65% and ROE of -6.11% reflect poor asset utilization
- Operating margin near zero at 0.15%
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid (yield N/A)
- Dividend strength score of 0/100
- Payout ratio is 0.00% due to lack of dividend
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$39.07
Analyst Target
$52.78
Upside/Downside
+35.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ATRC and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ATRC
AtriCure, Inc.
Primary
|
-33.0% | -7.6% | -3.2% | +24.0% | -3.6% | +0.0% |
|
OCUL
Ocular Therapeutix, Inc.
Peer
|
-43.9% | +53.6% | +18.3% | -25.4% | +3.2% | +5.8% |
|
MESO
Mesoblast Limited
Peer
|
-15.5% | +113.7% | +36.9% | -19.0% | +1.0% | -1.1% |
|
GLPG
Galapagos NV
Peer
|
-63.1% | -24.7% | +17.3% | -16.1% | -14.0% | -2.9% |
|
AUPH
Aurinia Pharmaceuticals Inc.
Peer
|
-22.4% | +77.0% | +81.0% | +62.7% | -10.7% | -2.1% |
ATR
AtriCure, Inc.
Primary
5Y
-33.0%
3Y
-7.6%
1Y
-3.2%
6M
+24.0%
1M
-3.6%
1W
+0.0%
OCU
Ocular Therapeutix, Inc.
Peer
5Y
-43.9%
3Y
+53.6%
1Y
+18.3%
6M
-25.4%
1M
+3.2%
1W
+5.8%
MES
Mesoblast Limited
Peer
5Y
-15.5%
3Y
+113.7%
1Y
+36.9%
6M
-19.0%
1M
+1.0%
1W
-1.1%
GLP
Galapagos NV
Peer
5Y
-63.1%
3Y
-24.7%
1Y
+17.3%
6M
-16.1%
1M
-14.0%
1W
-2.9%
AUP
Aurinia Pharmaceuticals Inc.
Peer
5Y
-22.4%
3Y
+77.0%
1Y
+81.0%
6M
+62.7%
1M
-10.7%
1W
-2.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-298.24
PEG Ratio
N/A
P/B Ratio
4.08
P/S Ratio
3.75
EV/Revenue
3.61
EV/EBITDA
-301.29
Market Cap
$1.94B
Profitability
Profit margins and return metrics
Profit Margin
-5.55%
Operating Margin
0.15%
Gross Margin
74.87%
ROE
-6.11%
ROA
-2.65%
Growth
Revenue and earnings growth rates
Revenue Growth
+15.8%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.16
Low debt
Current Ratio
3.87
Strong
Quick Ratio
2.71
Excellent
Cash/Share
$2.97
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-11
$N/A
2025-10-29
$-0.01
+91.3% surprise
2025-07-29
$-0.02
+87.7% surprise
2025-04-29
$-0.14
+37.3% surprise
Healthcare Sector Comparison
Comparing ATRC against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-6.11%
This Stock
vs
-88.14%
Sector Avg
-93.1%
(Below Avg)
Profit Margin
-5.55%
This Stock
vs
-16.28%
Sector Avg
-65.9%
(Weaker)
Debt to Equity
0.16
This Stock
vs
2.66
Sector Avg
-94.0%
(Less Debt)
Revenue Growth
15.8%
This Stock
vs
124.04%
Sector Avg
-87.3%
(Slower)
Current Ratio
3.87
This Stock
vs
4.47
Sector Avg
-13.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ATRC
AtriCure, Inc.
|
NEUTRAL | $1.94B | - | -6.1% | -5.6% | $39.07 | |
|
OCUL
Ocular Therapeutix, Inc.
|
NEUTRAL | $1.94B | - | -54.9% | -% | $8.91 | Compare |
|
MESO
Mesoblast Limited
|
BEARISH | $1.92B | - | -18.2% | -144.3% | $14.7 | Compare |
|
GLPG
Galapagos NV
|
NEUTRAL | $1.92B | 5.16 | 10.4% | 28.8% | $28.56 | Compare |
|
AUPH
Aurinia Pharmaceuticals Inc.
|
NEUTRAL | $1.92B | 26.42 | 20.7% | 29.3% | $14.53 | Compare |
ATRC
AtriCure, Inc.
NEUTRAL
Mkt Cap
$1.9B
P/E
-
ROE
-6.1%
Price
$39.07
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-31 | SEITH DOUGLAS J | Chief Operating Officer | Stock Award | 257 | $10,167 |
| 2025-12-10 | CARREL MICHAEL H | Chief Executive Officer | Gift | 4,000 | - |
| 2025-11-26 | NOZNESKY JUSTIN J | Officer | Sale | 5,166 | $192,640 |
| 2025-11-25 | WEHRWEIN SVEN A | Director | Option Exercise | 10,000 | $199,500 |
| 2025-11-25 | WEHRWEIN SVEN A | Director | Sale | 10,000 | $376,578 |
| 2025-11-21 | YUEN MAGGIE S. | Director | Sale | 3,000 | $107,160 |
| 2025-11-13 | CARREL MICHAEL H | Chief Executive Officer | Gift | 6,000 | - |
| 2025-09-12 | NOZNESKY JUSTIN J | Officer | Sale | 3,000 | $108,900 |
| 2025-08-22 | WEHRWEIN SVEN A | Director | Option Exercise | 5,000 | $99,750 |
| 2025-08-22 | WEHRWEIN SVEN A | Director | Sale | 5,000 | $185,000 |
| 2025-08-19 | WEHRWEIN SVEN A | Director | Option Exercise | 5,000 | $99,750 |
| 2025-08-19 | WEHRWEIN SVEN A | Director | Sale | 5,000 | $180,000 |
| 2025-08-08 | CARREL MICHAEL H | Chief Executive Officer | Gift | 10,000 | - |
| 2025-08-06 | GROVES REGINA E | Director | Sale | 2,452 | $90,283 |
| 2025-08-05 | DORAISWAMY VINAYAK | Officer | Sale | 2,500 | $91,450 |
SEITH DOUGLAS J
Chief Operating Officer
2025-12-31
257 shares
·
$10,167
CARREL MICHAEL H
Chief Executive Officer
2025-12-10
4,000 shares
NOZNESKY JUSTIN J
Officer
2025-11-26
5,166 shares
·
$192,640
WEHRWEIN SVEN A
Director
2025-11-25
10,000 shares
·
$199,500
WEHRWEIN SVEN A
Director
2025-11-25
10,000 shares
·
$376,578
YUEN MAGGIE S.
Director
2025-11-21
3,000 shares
·
$107,160
CARREL MICHAEL H
Chief Executive Officer
2025-11-13
6,000 shares
NOZNESKY JUSTIN J
Officer
2025-09-12
3,000 shares
·
$108,900
WEHRWEIN SVEN A
Director
2025-08-22
5,000 shares
·
$99,750
WEHRWEIN SVEN A
Director
2025-08-22
5,000 shares
·
$185,000
WEHRWEIN SVEN A
Director
2025-08-19
5,000 shares
·
$99,750
WEHRWEIN SVEN A
Director
2025-08-19
5,000 shares
·
$180,000
CARREL MICHAEL H
Chief Executive Officer
2025-08-08
10,000 shares
GROVES REGINA E
Director
2025-08-06
2,452 shares
·
$90,283
DORAISWAMY VINAYAK
Officer
2025-08-05
2,500 shares
·
$91,450
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
9 analysts
JP Morgan
2025-12-16
Overweight
Overweight
Canaccord Genuity
2025-10-30
Buy
Buy
Needham
2025-07-30
Buy
Buy
Past News Coverage
Recent headlines mentioning ATRC from our newsroom.
Newest → oldest
No matching news yet.